Renaissance Technologies
BOLT icon

Renaissance Technologies’s Bolt Biotherapeutics BOLT Stock Holding History

Renaissance Technologies’s Portfolio BOLT Stock Details BOLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$342K Sell
92,925
-5,700
-6% -$21.8K ﹤0.01% 2745
2026
Q2 		$380K Buy
98,625
+21,400
+28% +$100K ﹤0.01% 2705
2026
Q1 		$312K Buy
77,225
+22,200
+40% +$116K ﹤0.01% 2778
2025
Q4 		$301K Buy
55,025
+26,400
+92% +$142K ﹤0.01% 2760
2025
Q3 		$152K Buy
28,625
+10,300
+56% +$57.1K ﹤0.01% 3189
2025
Q2 		$106K Buy
18,325
+2,618
+17% +$17.3K ﹤0.01% 3292
2025
Q1 		$126K Buy
15,707
+605
+4% +$5.81K ﹤0.01% 3156
2024
Q4 		$162K Buy
15,102
+400
+3% +$4.84K ﹤0.01% 3217
2024
Q3 		$191K Buy
14,702
+865
+6% +$11.9K ﹤0.01% 3138
2024
Q2 		$208K Sell
13,837
-12,045
-47% -$238K ﹤0.01% 3036
2024
Q1 		$725K Buy
25,882
+3,618
+16% +$83.8K ﹤0.01% 2679
2023
Q4 		$499K Buy
22,264
+6,555
+42% +$128K ﹤0.01% 2778
2023
Q3 		$327K Sell
15,709
-8,488
-35% -$207K ﹤0.01% 2888
2023
Q2 		$619K Buy
24,197
+1,360
+6% +$43.2K ﹤0.01% 2751
2023
Q1 		$635K Buy
22,837
+760
+3% +$22.2K ﹤0.01% 2755
2022
Q4 		$574K Buy
22,077
+2,384
+12% +$65.3K ﹤0.01% 2875
2022
Q3 		$583K Sell
19,693
-7,236
-27% -$299K ﹤0.01% 2838
2022
Q2 		$1.1M Buy
26,929
+12,424
+86% +$482K ﹤0.01% 2647
2022
Q1 		$795K Buy
14,505
+10,060
+226% +$677K ﹤0.01% 2876
2021
Q4 		$436K Buy
4,445
+480
+12% +$91.1K ﹤0.01% 3142
2021
Q3 		$1M Buy
3,965
+941
+31% +$266K ﹤0.01% 2546
2021
Q2 		$935K Buy
+3,024
New +$1.23M ﹤0.01% 2697

Other funds holding BOLT

T3 Companies
T3 Companies New York $103M AUM 54.73% 1-Year Est. Return
Pfizer
Pfizer New York $164M AUM 53.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
SBI Securities
SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Renaissance Technologies's BOLT Position: Q3 2026 in Review

Renaissance Technologies reduced its Bolt Biotherapeutics (BOLT) stake by 5.8% in Q3 2026, selling an estimated $21.8K and leaving 92,925 shares worth $342K. The position accounts for ﹤0.01% of the portfolio, ranked #2745.

Renaissance Technologies first reported a position in BOLT in Q2 2021 and has held it in 22 quarters since. The position peaked at $1.1M in Q2 2022. 9 funds tracked by Wall St. Rank hold BOLT as of Q3 2026.

  • Renaissance Technologies held 92,925 shares of Bolt Biotherapeutics worth $342K as of Q3 2026.
  • Renaissance Technologies sold 5,700 Bolt Biotherapeutics shares in Q3 2026, an estimated $21.8K.
  • Bolt Biotherapeutics made up ﹤0.01% of Renaissance Technologies's portfolio in Q3 2026, its #2745 holding.
  • Renaissance Technologies first reported a position in Bolt Biotherapeutics in Q2 2021 and has held it in 22 quarters since.
  • Renaissance Technologies's Bolt Biotherapeutics position peaked at $1.1M in Q2 2022.
  • 9 funds tracked by Wall St. Rank held Bolt Biotherapeutics as of Q3 2026.

Based on Renaissance Technologies's 13F filing for Q3 2026, filed 12 Nov 2026.